期刊
JOURNAL OF CONTROLLED RELEASE
卷 91, 期 3, 页码 417-429出版社
ELSEVIER SCIENCE BV
DOI: 10.1016/S0168-3659(03)00271-2
关键词
taxanes; liposomes; PEGylated liposomes; pharmacokinetics; biodistribution
The taxanes, paclitaxel and docetaxel, are anticancer agents used in clinical trials against ovarian carcinoma, breast, lung and head/neck cancer. Paclitaxel, very insoluble in water, is generally formulated using Cremophor EL, Docetaxel, more soluble in water, is formulated using Tween 80 and ethanol. Tween 80, albeit less toxic than Cremophor EL, may be responsible of some toxic effects. To eliminate these vehicles and improve the drug's antitumor efficacy, taxanes have been incorporated in liposomes. We compared formulation, stability, biodistribution and pharmacokinetics of docetaxel in conventional and PEGylated liposomes. Of the several formulations examined, docetaxel-liposomes composed of ePC/PG/ CHOL 9:1:2 and ePC/PG/DSPE-PEG(2000)/CHOL 9:1:2:0.7 were the most effective. Both conventional and PEGylated docetaxel-liposomes were stable at 4degreesC after 15 days, whereas in the presence of serum at 37degreesC they were less stable. The IC50 values of docetaxel-liposomes, evaluated on HT-29 and Igrovl cell lines, remained very high. Pharmacokinetics and biodistribution were evaluated in Balb/c mice after i.v. injection of [C-14]docetaxel, formulated in Tween 80 or in H-3-labeled conventional or PEGylated liposomes. The t(1/2beta), which was low for docetaxel (52.3 min), rose to 260 min for conventional docetaxel-liposomes and to 665 min for PEGylated docetaxel liposomes. Biodistribution studies confirmed the pharmacokinetics. (C) 2003 Published by Elsevier B.V.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据